rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
3
|
pubmed:dateCreated |
2003-2-24
|
pubmed:abstractText |
The role of p53 in modulating apoptosis has suggested that it may affect efficacy of anticancer agents. We prospectively evaluated p53 alterations in 73 patients with locally advanced breast cancer (IIIB) submitted to neoadjuvant chemotherapy.
|
pubmed:commentsCorrections |
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0923-7534
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
14
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
428-32
|
pubmed:dateRevised |
2006-4-24
|
pubmed:meshHeading |
pubmed-meshheading:12598349-Adult,
pubmed-meshheading:12598349-Aged,
pubmed-meshheading:12598349-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12598349-Apoptosis,
pubmed-meshheading:12598349-Breast Neoplasms,
pubmed-meshheading:12598349-Doxorubicin,
pubmed-meshheading:12598349-Female,
pubmed-meshheading:12598349-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:12598349-Genes, p53,
pubmed-meshheading:12598349-Humans,
pubmed-meshheading:12598349-Immunohistochemistry,
pubmed-meshheading:12598349-Middle Aged,
pubmed-meshheading:12598349-Neoadjuvant Therapy,
pubmed-meshheading:12598349-Paclitaxel,
pubmed-meshheading:12598349-Predictive Value of Tests,
pubmed-meshheading:12598349-Prospective Studies,
pubmed-meshheading:12598349-Treatment Outcome,
pubmed-meshheading:12598349-Tumor Markers, Biological,
pubmed-meshheading:12598349-Tumor Suppressor Protein p53
|
pubmed:year |
2003
|
pubmed:articleTitle |
Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer.
|
pubmed:affiliation |
Department of Medical Oncology, Hospital do Câncer de São Paulo, São Paulo, Brazil. aanelli@node1.com.br
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|